These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24341496)

  • 1. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.
    Wang YM; Jawa V; Ma M
    Bioanalysis; 2014 Jan; 6(1):79-87. PubMed ID: 24341496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioanalytical considerations in the comparability assessment of biotherapeutics.
    Lee JW; Wang YM; Moxness M; DeSilva B
    Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
    Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.
    Shah DK; Barletta F; Betts A; Hansel S
    Bioanalysis; 2013 May; 5(9):989-92. PubMed ID: 23641690
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory considerations for development of bioanalytical assays for biotechnology products.
    Swann PG; Shapiro MA
    Bioanalysis; 2011 Mar; 3(6):597-603. PubMed ID: 21417729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PK-PD modeling of protein drugs: implications in assay development.
    Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
    Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue bioanalysis of biotherapeutics and drug targets to support PK/PD.
    Neubert H; Fountain S; King L; Clark T; Weng Y; O'Hara DM; Li W; Leung S; Ray C; Palandra J; Ocaña MF; Chen J; Ji C; Wang M; Long K; Gorovits B; Fluhler E
    Bioanalysis; 2012 Nov; 4(21):2589-604. PubMed ID: 23173794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.
    Hussain A; Gorovits B; Leal M; Fluhler E
    Bioanalysis; 2014 Jan; 6(1):21-32. PubMed ID: 24341492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Perspectives on Ligand-Binding Assay Practices in the Quantification of Circulating Therapeutic Proteins for Biosimilar Biological Product Development.
    Thway TM; Wang YM; Booth BP; Maxfield K; Huang SM; Zineh I
    AAPS J; 2019 Dec; 22(1):15. PubMed ID: 31858313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments.
    Marini JC; Anderson M; Cai XY; Chappell J; Coffey T; Gouty D; Kasinath A; Koppenburg V; Oldfield P; Rebarchak S; Bowsher RR
    AAPS J; 2014 Nov; 16(6):1149-58. PubMed ID: 25277165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.
    Lee JW; Salimi-Moosavi H
    Bioanalysis; 2012 Oct; 4(20):2513-23. PubMed ID: 23157359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.
    Wang YM; Chow AT
    J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.
    Kaur S; Xu K; Saad OM; Dere RC; Carrasco-Triguero M
    Bioanalysis; 2013 Jan; 5(2):201-26. PubMed ID: 23330562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
    Shah DK
    J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of bioanalytical measurements using PK-PD modeling and simulation: implications for antibody-drug conjugate development.
    Khot A; Sharma S; Shah DK
    Bioanalysis; 2015; 7(13):1633-48. PubMed ID: 26226312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
    Lin K; Tibbitts J; Shen BQ
    Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of free and total target measurements as target engagement and efficacy biomarkers in biotherapeutic development--opportunities and challenges.
    Zheng S; McIntosh T; Wang W
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S75-84. PubMed ID: 25707966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.
    Kumar S; King LE; Clark TH; Gorovits B
    Bioanalysis; 2015; 7(13):1605-17. PubMed ID: 26226310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old to new ligand-binding assay method modifications.
    Stouffer B; Stocker D
    Bioanalysis; 2016 Jul; 8(13):1403-7. PubMed ID: 27302308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.